Vironova
Advertisement
Articles by Vironova
How Artificial Intelligence Can Address Analytical Challenges in Gene Therapies and Vaccines
ByVironova
Sponsored Content
Expert panelists share experiences about how to overcome challenges and needs for supporting analytical data in the development of commercial processes for viral-based therapies. How artificial intelligence plays a role in enabling automation for unbiased results to correlate process impact on critical quality attributes. Live: Thursday, Sept. 26, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Sept. 26, 2020 Register free
Advertisement
Latest Updated Articles
- Rising Demands for Analytics of Viral Vectors
November 7th 2019
Advertisement
Advertisement
Trending on BioPharm International
1
Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
2
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
3
FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease
4
The BioPharm Brief: Gilead’s Oral IL-23R Bet, Roche’s Trispecific Deal, and Treasury’s Biotech Investment Proposal
5